Bladder preservation with chemo, immunotherapy, and radiation
Part of Cancer, Kidney & urinary clinical trials.
This study tests a combination of chemotherapy, immunotherapy, and radiation to treat muscle-invasive bladder cancer while trying to avoid bladder removal. It compares this approach to a watch-and-wait strategy, and also looks at adding maintenance immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed muscle-invasive bladder cancer (stage T2-T4N0M0) or recurrent non-muscle invasive bladder cancer.
- Your cancer must be a type called transitional cell carcinoma (the most common kind).
- You must be well enough to carry out daily activities (ECOG performance status 0 or 1).
- You must have adequate kidney, liver, and blood cell counts as determined by blood tests.
- You cannot have had prior chemotherapy, radiation, or immunotherapy for bladder cancer.
- You must not have an active autoimmune disease or other serious medical condition that would make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how the immune environment around a muscle-invasive bladder tumor changes after you receive treatment before surgery (neoadjuvant therapy). The goal is to understand why some tumors respond better, which could help guide future treatments.
This trial compares two main treatments for muscle-invasive bladder cancer: radical cystectomy (surgery to remove the bladder) and a combination of chemotherapy and radiation (chemo-radiation). The goal is to see which approach is better for patients whose cancer has not spread widely.
This trial studies a bladder-sparing treatment plan that uses MRI to guide therapy for muscle-invasive bladder cancer. It combines maximal tumor removal, chemotherapy, and radiation to avoid bladder removal.
This study follows people with muscle-invasive bladder cancer who choose to keep their bladder (instead of removing it) after receiving chemotherapy, immunotherapy, or an ADC drug. It aims to see how well this approach works and what side effects may occur.
This study tests whether adding immunotherapy drugs (nivolumab alone or nivolumab plus ipilimumab) to standard chemo-radiation can control muscle-invasive bladder cancer while helping people keep their bladder. It aims to find a safer, effective curative treatment for people who want to avoid bladder removal (cystectomy).
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.